Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul V Viscuse

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Current Treatment Options in Cardiovascular Medicine|March 3, 2018
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation CarriersKelly C Gast, Paul V Viscuse, Somaira Nowsheen, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2021
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate CancerDaniel Westaby, Paul V Viscuse, Rahul Ravilla, et al.
Frontiers in Oncology|March 22, 2021
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity ReactionPaul V Viscuse, Mario L Marques-Piubelli, Meghan M Heberton, et al.
Cancers|December 23, 2023
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) EnvironmentsPaul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, et al.
The Oncologist|November 30, 2023
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint TherapyAndrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, et al.
International Journal of Molecular Sciences|January 25, 2025
Clinical and Genomic Features of Androgen Indifferent Prostate CancerJack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, et al.
Cancers|May 27, 2026
Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional AnalysisEvan R Adler, Anwaruddin Mohammad, Pankaj Kumar, et al.
European Urology Focus|March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint TherapyAndrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate CancerAna M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Current Treatment Options in Cardiovascular Medicine|March 3, 2018
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation CarriersKelly C Gast, Paul V Viscuse, Somaira Nowsheen, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2021
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate CancerDaniel Westaby, Paul V Viscuse, Rahul Ravilla, et al.
Frontiers in Oncology|March 22, 2021
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity ReactionPaul V Viscuse, Mario L Marques-Piubelli, Meghan M Heberton, et al.
Cancers|December 23, 2023
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) EnvironmentsPaul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, et al.
The Oncologist|November 30, 2023
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint TherapyAndrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, et al.
International Journal of Molecular Sciences|January 25, 2025
Clinical and Genomic Features of Androgen Indifferent Prostate CancerJack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, et al.
Cancers|May 27, 2026
Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional AnalysisEvan R Adler, Anwaruddin Mohammad, Pankaj Kumar, et al.
European Urology Focus|March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint TherapyAndrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate CancerAna M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.
Pageof 2